Improving the Administration, Bioavailability, Safety, and Efficacy of Treatments
MOUNTAIN VIEW, Calif., March 19 /PRNewswire/ -- Based on its recent analysis of the ocular drug delivery market, Frost & Sullivan recognizes Novagali Pharma with the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb and Eyeject.
It is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers. These beneficial natural defenses, which protect the eyes and block foreign substances, also greatly limit the usefulness of topical treatments for treating them when distressed or diseased. This is true, in particular, for diseases of the posterior of the eye.
"Novagali recognizes this as an opportunity and is working diligently with its proprietary emulsion technologies to overcome both pharmacological and drug delivery challenges in the eye," says Frost & Sullivan Research Analyst Misty Hughes. "With research truly encompassing all segments of the eye, Novagali's Novasorb is optimized to treat a number of diseases by improving drug delivery to the front of the eye, while the minimally-invasive Eyeject intra-ocular platform offers improvements over existing implant technology in treating challenging diseases of the eye's posterior."
Novasorb is a cationic emulsion technology platform being investigated to treat dry eye, glaucoma, allergies, and anterior uveitis. As the effective treatment of surface ocular conditions is often limited by dispersion and lubrication, Novasorb technology increases the abso
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved